Corcept Completes Enrollment in Phase 4 CATALYST Trial
Go back to Corcept Completes Enrollment in Phase 4 CATALYST Trial| Corcept Therapeutics, Inc. (NASDAQ: CORT) | Delayed: 116.10 -2.41 (2.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $118.51 | 52 Week High | $10.00 | |||
| Open | $119.00 | 52 Week Low | $3.22 | |||
| Day High | $120.44 | P/E | N/A | |||
| Day Low | $114.51 | EPS | $-0.46 | |||
| Volume | 800,797 | |||||
